Select area to zoom
Created with Highcharts 11.1.0Jul '24Oct '24Jan '25Apr '255.002.22

Profile

Edit
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
URL https://www.aldeyra.com
Investor Relations URL https://ir.aldeyra.com/
HQ State/Province Massachusetts
Sector Health Care
Industry Biotechnology
Next Earnings Release Aug. 01, 2025 (est.)
Last Earnings Release May. 14, 2025
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Edit
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
URL https://www.aldeyra.com
Investor Relations URL https://ir.aldeyra.com/
HQ State/Province Massachusetts
Sector Health Care
Industry Biotechnology
Next Earnings Release Aug. 01, 2025 (est.)
Last Earnings Release May. 14, 2025
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A
Quickflows